Sirolimus use and cancer incidence among US kidney transplant recipients. (Q53226241)

12 May 2018

title

Sirolimus use and cancer incidence among US kidney transplant recipients. (English)

1 reference

12 May 2018

1 reference

1

1 reference

12 May 2018

Dorry Segev

8

object named as

D L Segev

1 reference

12 May 2018

author name string

S K Gustafson

2

1 reference

12 May 2018

B L Kasiske

3

1 reference

12 May 2018

A K Israni

4

1 reference

12 May 2018

J J Snyder

5

1 reference

12 May 2018

G P Hess

6

1 reference

12 May 2018

E A Engels

7

1 reference

12 May 2018

language of work or name

English

0 references

publication date

17 December 2014

1 reference

12 May 2018

American Journal of Transplantation

published in

1 reference

12 May 2018

volume

15

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

129-136

1 reference

12 May 2018

Spectrum of cancer risk among US solid organ transplant recipients

cites work

1 reference

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

21 January 2018

1 reference

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

21 January 2018

1 reference

Involvement of the Akt/mTOR pathway on EGF-induced cell transformation

21 January 2018

1 reference

Immunosuppressive drugs for kidney transplantation.

21 January 2018

1 reference

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer

21 January 2018

1 reference

Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus

21 January 2018

1 reference

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

21 January 2018

1 reference

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial

21 January 2018

1 reference

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States

21 January 2018

1 reference

Report of a consensus conference on transplant program quality and surveillance

21 January 2018

1 reference

Targeting mTOR in cancer: renal cell is just a beginning

21 January 2018

1 reference

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma

21 January 2018

1 reference

Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.

21 January 2018

1 reference

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/AJT.12969

1 reference

12 May 2018

1 reference

12 May 2018